PE20231296A1 - Formulaciones a largo plazo - Google Patents

Formulaciones a largo plazo

Info

Publication number
PE20231296A1
PE20231296A1 PE2023000037A PE2023000037A PE20231296A1 PE 20231296 A1 PE20231296 A1 PE 20231296A1 PE 2023000037 A PE2023000037 A PE 2023000037A PE 2023000037 A PE2023000037 A PE 2023000037A PE 20231296 A1 PE20231296 A1 PE 20231296A1
Authority
PE
Peru
Prior art keywords
long
pharmaceutical compositions
term formulations
formulations
term
Prior art date
Application number
PE2023000037A
Other languages
English (en)
Inventor
Rene Holm
Iwan Caroline Vervoort
Wenyu Dong
Miriam Colombo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20231296A1 publication Critical patent/PE20231296A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Esta invencion se refiere a composiciones farmaceuticas para la administracion por via intramuscular o inyeccion subcutanea, que comprende micro o nanoparticulas del compuesto bedaquilina suspendido en un vehiculo acuoso farmaceuticamente aceptable, y que comprende PEG4000 como un modificador de superficie, y al uso de tales composiciones farmaceuticas en el tratamiento y profilaxis de una infeccion por micobacterias patogenas.
PE2023000037A 2020-07-09 2021-07-08 Formulaciones a largo plazo PE20231296A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20185105 2020-07-09
PCT/EP2021/068956 WO2022008643A1 (en) 2020-07-09 2021-07-08 Long-acting formulations

Publications (1)

Publication Number Publication Date
PE20231296A1 true PE20231296A1 (es) 2023-08-22

Family

ID=71575093

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000037A PE20231296A1 (es) 2020-07-09 2021-07-08 Formulaciones a largo plazo

Country Status (12)

Country Link
US (1) US20230241051A1 (es)
EP (1) EP4178546A1 (es)
JP (1) JP2023533014A (es)
KR (1) KR20230038521A (es)
CN (1) CN115867259A (es)
AU (1) AU2021303490A1 (es)
BR (1) BR112023000220A2 (es)
CA (1) CA3182425A1 (es)
CO (1) CO2023001340A2 (es)
MX (1) MX2023000439A (es)
PE (1) PE20231296A1 (es)
WO (1) WO2022008643A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183276A1 (en) * 2022-03-22 2023-09-28 University Of Southern California Adjunctive treatment of mycobacterial diseases
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
CN1325475C (zh) 2002-07-25 2007-07-11 詹森药业有限公司 喹啉衍生物及其作为分枝杆菌抑制剂的应用
JP2007501683A (ja) 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2606675C (en) 2005-05-25 2013-02-19 Janssen Pharmaceutica N.V. Process for preparing (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
DK2040671T3 (en) 2006-06-23 2018-05-07 Janssen Sciences Ireland Uc AURAL SUSPENSIONS OF TMC278
US9421194B2 (en) * 2010-04-05 2016-08-23 Rutgers, The State University Of New Jersey Lung targeting dual drug delivery system
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
MX362344B (es) 2011-04-15 2019-01-11 Janssen Pharmaceutica Nv Nanosuspensiones de farmacos secadas por congelamiento.
PL3651736T3 (pl) * 2017-07-14 2021-12-20 Janssen Pharmaceutica Nv Formulacje o długotrwałym działaniu

Also Published As

Publication number Publication date
WO2022008643A1 (en) 2022-01-13
JP2023533014A (ja) 2023-08-01
CN115867259A (zh) 2023-03-28
AU2021303490A1 (en) 2023-03-09
EP4178546A1 (en) 2023-05-17
US20230241051A1 (en) 2023-08-03
CO2023001340A2 (es) 2023-02-27
MX2023000439A (es) 2023-02-09
BR112023000220A2 (pt) 2023-01-31
KR20230038521A (ko) 2023-03-20
CA3182425A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
PE20231296A1 (es) Formulaciones a largo plazo
PE20200336A1 (es) Formulaciones a largo plazo
ECSP22018209A (es) Nanopart?culas lip?dicas mejoradas para el suministro de ?cidos nucleicos
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CO2019012893A2 (es) Composiciones farmacéuticas de atropina
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
UY30431A1 (es) Suspensiones acuosas de tmc278
CO2020001502A2 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción heterobiarilo, conjugados de estos y métodos y usos de estos
DOP2017000175A (es) Dinucleótidos cíclicos útiles en el tratamiento del cáncer
CO2020001498A2 (es) Derivados de 6-amino-7,9-dihidro-8h-purina-8-ona como agonistas inmunoestimulantes del receptor 7 tipo toll (tlr7)
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
NI201800023A (es) Compuestos antivirales de fosfodiamida de éster de beta-aminoácido
AR110419A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
CL2020002252A1 (es) Formulación oftálmica.
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
CO6640318A2 (es) Formas de dosificación oral de bendamustina
UY38982A (es) Composiciones farmacéuticas
CL2018002705A1 (es) Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales
CO2021002980A2 (es) Formulaciones de dendrímeros
CL2022003689A1 (es) Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4)
AR122350A1 (es) Composiciones farmacéuticas
AR110598A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
EA202090287A1 (ru) Составы пролонгированного действия